Patent Examiner Sergio Coffa
Art Unit 1658 · Peptide & Protein Therapeutics · Tech Center 1600 · 309 applications filed 2021–2026
Sergio Coffa is a USPTO patent examiner in Art Unit 1658 (Peptide & Protein Therapeutics) with 309 applications from filing years 2021–2026. Examiner Coffa's allowance rate is 66.7%, below the 82.1% USPTO average for applications filed in the same years. The examiner ranks harder than 77% of examiners. In 2021, decided applications with an examiner interview were allowed 29.7 percentage points more often than those without.
Data through November 2026 from USPTO Patent Center (formerly PAIR) · Methodology
Overview
FreeExaminer details
- Art unit1658 · Peptide & Protein Therapeutics
- Title / gradePrimary Patent Examiner · GS-14
- Service15 years
- PhoneOn each office action
- Email[email protected]
- In USPTO recordsCOFFA, SERGIO
Examiner Coffa can allow an application without a supervisory sign-off.
How to improve your odds with Examiner Coffa
- The data favors an interview. Interviewed cases were allowed more often in all 3 measured years, by 29.7 to 39.3 points.
- Plan for the timeline. First office action averages 755 days vs the 620-day USPTO norm.
- Expect a §112. Definiteness & disclosure is the most-issued rejection (202), and applicants overcame it 59.0% of the time.
- The data favors an RCE here. Cases with an RCE were allowed more often in all 3 measured years, by 10.3 to 27.7 points.
Historical patterns from this examiner's past cases, shown for general information. This is not legal advice and does not predict the outcome of any specific application. Decisions about interviews, RCEs, and claim strategy should be made with a licensed patent attorney or agent.
Rejection patterns & how they get overcome
FreeOf the 49 winning responses to Examiner Coffa's §112 rejections that Boundly has classified, 34 (69%) amended the claims and argued, 8 argued without amending, and 7 amended without arguing. Each winning response, with its arguments and claim amendments, is in the file wrapper.
Just got an office action from Examiner Coffa?
Draft your response with Examiner Coffa's record and Art Unit 1658's history in view, including the rejection patterns, the interview record, and the arguments that have overcome them. See office action responses in AI Studio.
Trends
| Year | Interview rate | Allowance w/ interview | Allowance w/o | Delta |
|---|---|---|---|---|
| 2023 | 16.4% | 87.5% | 50.0% | +37.5pp |
| 2022 | 11.1% | 100.0% | 60.7% | +39.3pp |
| 2021 | 25.6% | 84.2% | 54.5% | +29.7pp |
RCE behavior
Allowance after a Request for Continued Examination versus without one, per year. Use it to judge whether an RCE is worth the cost in front of Examiner Coffa.
| Year | RCE rate | Allowance w/ RCE | Allowance w/o | Delta |
|---|---|---|---|---|
| 2023 | 23.6% | 83.3% | 55.6% | +27.7pp |
| 2022 | 28.3% | 73.3% | 63.0% | +10.3pp |
| 2021 | 37.2% | 76.9% | 54.2% | +22.7pp |
Recent outcomes
Free🔒 Case detail for members| App # | Title | Outcome | OAs | Arguments & redline |
|---|---|---|---|---|
| 18/099258 | Calcium Independent Phosphatidylserine Binding Compounds for Detecting Phosphatidylserine Positive Cells | Patented | 4 | 🔒 View |
| 17/714896 | Animal-Free Dietary Collagen | Patented | 3 | 🔒 View |
| 18/433336 | Methods for Treating Myelin Associated Diseases and Mitochondria Associated Diseases | Patented | 3 | 🔒 View |
| 17/946816 | Methods and Compositions for the Treatment of Viral Disease Using Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) | Patented | 2 | 🔒 View |
Art Unit 1658 technology
Frequently asked questions
What is Examiner Sergio Coffa's allowance rate?
Is Examiner Coffa a hard examiner?
Do examiner interviews help with Examiner Coffa?
What is Examiner Coffa's most common rejection?
Is an RCE worth filing with Examiner Coffa?
How long until the first office action from Examiner Coffa?
How do I contact Examiner Sergio Coffa?
Put Examiner Coffa's data to work on your next response.
Full file-wrapper detail, winning arguments, and AI-assisted drafting in one workspace.